Effects of amantadine sulfate on cognitive impairments in patients with Parkinson's disease

Neuroscience and Behavioral Physiology

Volumn 41, Issue 6, 2011, Pages 567-573

  Yablonskaya, A Yu ^a   Fedorova, N V ^a,b   Belgusheva, M E ^a  

^a Russian Postgraduate Medical Academy   (Russian Federation)

^b Center for Extrapyramidal Studies   (Russian Federation)

Author keywords

amantadine sulfate; cognitive impairments; Parkinson's disease; treatment

Indexed keywords

AMANTADINE SULFATE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; DRUG RESPONSE; FEMALE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 79961210255     PISSN: 00970549     EISSN: 1573899X     Source Type: Journal    
DOI: 10.1007/s11055-011-9456-z     Document Type: Article

References (44)

1. R. K. Arakelyan, E. A. Nerobkova, and E. A. Katunina, "Functional activity of the brain in patients with Parkinson's disease during treatment with amantadine sulfate," Zh. Nevrol. Psikhiat., 4 (2005).
2. D. V. Artemiev and Zh. M. Glozman, "Impairments to higher mental functions in Parkinson's disease," in: Progress in Neurogeriatrics [in Russian], N. N. Yakhno and I. V. Damulin (eds.), Moscow (1995), Vol. 1, pp. 46-58.
3. I. V. Damulin, Dementia in Parkinson's Disease. Advice for Physicians [in Russian], Moscow (2005).
4. VV Zakharov 2006 Dementia in Parkinson's disease Nevrol. Zh., Addendum 1 11 13 18
5. V. V. Zakharov, Impairments to Cognitive Functions in Parkinson's Disease and Symptomatic Parkinsonism [in Russian], Author's Abstract of Doctoral Thesis in Medical Sciences, Moscow (2003), pp. 36-40.
6. VV Zakharov PV Yaroslavtseva NN Yakhno 2003 Cognitive impairments in Parkinson's disease Nevrol. Zh. 2 11 13
7. VV Zakharov NN Yakhno 2004 Moderate cognitive impairment in the elderly: diagnosis and treatment Rus. Med. Zh. 10 573 576
8. OS Levin LA Batukaeva IG Smolentseva 2008 Diagnosis and treatment of dementia in Parkinson's disease Zh. Nevrol. Psikhiat. 6 91 97
9. OS Levin LV Golubeva 2006 Heterogeneity of moderate cognitive impairment: diagnostic and therapeutic aspects Konsilium 12 106 110
10. ICD-10. International Classification of Diseases and Health- Related Problems [Russian translation], 10th edition, Vol. 1, WHO, Geneva (1995).
11. AA Pilipovich VL Golubev 2005 Effects of Pronoran on cognitive and affective impairments in Parkinson's disease Zh. Nevrol. Psikhiat. 4 41 47 (Pubitemid 44077223)
12. A. N. Sadikova, Correction of Clinical, Neuropsychological, and Computerized Tomography Data in Parkinson's Disease [in Russian], Author's Abstract of Master's Thesis in Medical Sciences, Moscow (1977).
13. AD Stepkina VV Zakharov NN Yakhno 2005 Cognitive impairments on progression of Parkinson's disease Zh. Nevrol. Psikhiat. 10 13 19 (Pubitemid 44077244)
14. NN Yakhno 2006 Cognitive impairments in the neurology clinic Nevrol. Zh., Addendum 1 11 4 12
15. AL Benton NR Varney K Hamsher 1978 Visuospatial judgement: a clinical test Arch. Neurol. 35 364 367 655909 1:STN:280:DyaE1c7os1ahtQ%3D%3D
16. K Bronnick M Emre R Lane, et al. 2007 Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease J. Neurol. Neurosurg. Psychiat. 78 1064 1068 17287236 10.1136/jnnp.2006.108076
17. P Caspar C Duyckaerts, et al. 1991 Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease Ann. Neurol. 30 365 374 10.1002/ana.410300308
18. JL Cummings 2005 Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease J. Neurol. Neurosurg. Psychiat. 76 903 904 15965192 10.1136/jnnp.2004.061499 1:STN:280:DC%2BD2Mzhs1Cmug%3D%3D (Pubitemid 40909544)
19. B Dubois A Slachevsky I Litvan B Pillon 2000 The FAB: a frontal assessment battery at bedside Neurology 55 1621 1626 11113214 1:STN:280:DC%2BD3M%2FnvFSrsA%3D%3D
20. M Emre D Aarsland R Brown, et al. 2007 Clinical diagnostic criteria for dementia associated with Parkinson's disease Mov. Dis. 22 1689 1707 10.1002/mds.21507 (Pubitemid 47597592)
21. M Emre 2003 Dementia associated with Parkinson's disease Lancet Neurol. 2 229 237 12849211 10.1016/S1474-4422(03)00351-X 1:CAS:528:DC%2BD3sXkvVKqt70%3D (Pubitemid 37443310)
22. S. Fahn and R. Eiton, Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's Disease, S. Fahn, C. Marsden, and D. Calne (eds.), McMillan Healthcare Information (1987), Vol. 5, pp. 153-163.
23. MF Folstein SE Folstein PR McHugh 1975 Mini Mental State: a practical guide for grading the mental state of patients for the clinician J. Psychiatr. Res. 12 189 198 1202204 10.1016/0022-3956(75)90026-6 1:STN:280: DyaE28%2FntFKjtw%3D%3D
24. JE Galvin J Pollack JC Morris 2006 Clinical phenotype of Parkinson Disease dementia Neurology 67 1605 1611 17101891 10.1212/01.wnl.0000242630. 52203.8f (Pubitemid 44747931)
25. G Gianutsos S Chute JP Dunne 1985 Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine Eur. J. Pharmacol. 110 357 361 2861102 10.1016/0014-2999(85)90564-3 1:CAS:528:DyaL2MXktVSmsbo%3D (Pubitemid 15067699)
26. J. Golomb, A. Kluger, and S. H. Ferris, Clinician's Manual on Mild Cognitive Impairment, Science Press, London (2001).
27. P Hobson J Meara 2004 Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom Mov. Dis. 19 1043 1049 10.1002/mds.20216 (Pubitemid 39302836)
28. M Hoehn MD Yahr 1967 Parkinsonism: onset, progression and mortality Neurology 17 5 427 442 6067254 1:STN:280:DyaF2s7jvFSgsg%3D%3D
29. R Inzelberg U Bonuccelli, et al. 2006 Association between amantadine and the onset of dementia in Parkinson's disease Mov. Dis. 2 9 1375 1379 10.1002/mds.20968 (Pubitemid 44613288)
30. DM Jacobs K Marder L Cote, et al. 1995 Neuropsychological characteristics of preclinical dementia in Parkinson's disease Neurology 45 1691 1696 7675228 1:STN:280:DyaK2MvgsFKhug%3D%3D
31. J. Kaplan, H. Goodglass, and S. Weintraub, The Boston Naming Test, Boston (1978).
32. PL Le Bars MM Katz NA Berman 1997 Placebo-controlled, double-blind, randomized trial of an extract of Gingko biloba for dementia J. Am. Med. Assoc. 278 1327 1332 10.1001/jama.278.16.1327 (Pubitemid 27449692)
33. G Lewy DM Jacobs 2002 Memory and executive function impairments predict dementia in Parkinson's disease Mov. Dis. 17 6 1221 1226 10.1002/mds.10280 (Pubitemid 36050002)
34. M. D. Lezak, Neuropsychology Assessment, New York University Press, New York (1983).
35. MA Malone K Jerchner JM Swanson 1997 Hemispheric processing and methylphenidate effects in attention deficit hyperactivity disorder J. Child Neurol. 9 2 181 10.1177/088307389400900216
36. K Marder MZ Tang L Cote Y Stern 1995 The frequency and associated risk factors for dementia in patients with Parkinson's disease Arch. Neurol. 52 695 701 7619026 1:STN:280:DyaK2MzksVegtQ%3D%3D
37. S. Mattis, "Mental state examination for organic mental syndrome in the elderly patient," in: Geriatric Psychiatry, L. Bellack and T. B. Karasu (eds.), New York (1976).
38. K Palmer V Jelic B Winblad 2003 Preface: mild cognitive impairment Acta Neurol. Scand. 107 Supplement 179 5 6 10.1034/j.1600-0404.107.s179.1.x (Pubitemid 41737329)
39. RF Peppard WR Martin GD Carr, et al. 1992 Cerebral glucose metabolism in Parkinson's disease with and without dementia Arch. Neurol. 49 1262 1268 1449406 1:STN:280:DyaK3s%2FotVCktg%3D%3D
40. RS Peterson GE Smith SC Waring, et al. 1999 Mild cognitive impairment: clinical characterization and outcome Arch. Neurol. 56 303 308 10.1001/archneur.56.3.303 (Pubitemid 29120227)
41. RS Peterson J Touchon 2005 Consensus on mild cognitive impairment Res. Pract. Alzheimer's Dis. 10 24 32
42. W Poewe E Wolters M Emre, et al. 2006 Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study Mov. Dis. 21 4 456 461 10.1002/mds.20700
43. PR von Voigtlander KE Moore 1937 Dopamine release from the brain in vivo by amantadine Science 174 408 410 10.1126/science.174.4007.408
44. A. R. Young et al., in: Excitatory Amino Acids and Synaptic Transmission, Academic Press Harcourt Brace and Co., New York, pp. 29-40.